相似文献
1
Is the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids?
J Fungi (Basel). 2020 Nov 13;6(4):286. doi: 10.3390/jof6040286.
2
Candidemia in COVID-19 treated with corticosteroids and tocilizumab.
Clin Case Rep. 2021 Sep 21;9(9):e04858. doi: 10.1002/ccr3.4858. eCollection 2021 Sep.
3
Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010.
J Microbiol Immunol Infect. 2014 Apr;47(2):95-103. doi: 10.1016/j.jmii.2012.08.025. Epub 2012 Oct 11.
4
Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.
Intensive Care Med. 1997 Jan;23(1):23-30. doi: 10.1007/s001340050286.
5
Breakthrough candidemia after the introduction of broad spectrum antifungal agents: A 5-year retrospective study.
Med Mycol. 2018 Jun 1;56(4):406-415. doi: 10.1093/mmy/myx077.
6
Candidemia in a public hospital in Northeastern Brazil: Epidemiological features and risk factors in critically ill patients.
Rev Iberoam Micol. 2019 Oct-Dec;36(4):181-185. doi: 10.1016/j.riam.2019.06.003. Epub 2019 Nov 20.
7
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Clin Infect Dis. 2009 Jun 15;48(12):1695-703. doi: 10.1086/599039.
8
Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: a retrospective study from 2011 to 2017 in a teaching hospital in China.
Antimicrob Resist Infect Control. 2019 May 29;8:89. doi: 10.1186/s13756-019-0534-2. eCollection 2019.
9
Risk factors for candidemia mortality in hospitalized children.
J Pediatr (Rio J). 2017 Mar-Apr;93(2):165-171. doi: 10.1016/j.jped.2016.05.007. Epub 2016 Oct 3.
10
Clinical characteristics and predictors of mortality in patients with candidemia: a six-year retrospective study.
Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1717-1724. doi: 10.1007/s10096-018-3304-9. Epub 2018 Jul 20.
引用本文的文献
1
Characterization of COVID-19-Associated Candidemia Among Burn Patients.
J Clin Lab Anal. 2025 May;39(10):e70031. doi: 10.1002/jcla.70031. Epub 2025 Apr 8.
2
Evaluation of candidemia cases in the intensive care unit of a tertiary training hospital during the period of COVID-19 pandemic.
BMC Infect Dis. 2025 Feb 28;25(1):288. doi: 10.1186/s12879-025-10688-x.
3
Comparison of clinical characteristics and outcomes in candidaemia patients with and without COVID-19: a multicentre retrospective study.
BMC Infect Dis. 2024 Dec 28;24(1):1473. doi: 10.1186/s12879-024-10373-5.
4
Investigation of risk factors for invasive pulmonary aspergillosis among patients with COVID-19.
Sci Rep. 2024 Sep 2;14(1):20364. doi: 10.1038/s41598-024-71455-7.
5
A prediction model for secondary invasive fungal infection among severe SARS-CoV-2 positive patients in ICU.
Front Cell Infect Microbiol. 2024 Jul 8;14:1382720. doi: 10.3389/fcimb.2024.1382720. eCollection 2024.
6
Risk analysis of candidemia and its effect on mortality in COVID 19 and non COVID 19 patients.
Iran J Microbiol. 2024 Apr;16(2):236-242. doi: 10.18502/ijm.v16i2.15357.
7
Mapping the Burden of Fungal Diseases in the United Arab Emirates.
J Fungi (Basel). 2024 May 15;10(5):353. doi: 10.3390/jof10050353.
8
Epidemiological Assessment and Risk Factors for Mortality of Bloodstream Infections by sp. and the Impact of the COVID-19 Pandemic Era.
J Fungi (Basel). 2024 Apr 3;10(4):268. doi: 10.3390/jof10040268.
9
Candidemia in critically ill COVID-19 patients: Risk factors and impact on mortality.
Heliyon. 2024 Mar 15;10(6):e28033. doi: 10.1016/j.heliyon.2024.e28033. eCollection 2024 Mar 30.
10
Changing Epidemiology of Clinical Isolates of Species during the Coronavirus Disease 2019 Pandemic: Data Analysis from a Korean Tertiary Care Hospital for 6 Years (2017-2022).
J Fungi (Basel). 2024 Mar 2;10(3):193. doi: 10.3390/jof10030193.
本文引用的文献
1
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022.
2
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
3
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Oct 6;324(13):1298-1306. doi: 10.1001/jama.2020.16761.
4
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
5
Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study.
Lancet Glob Health. 2020 Aug;8(8):e1018-e1026. doi: 10.1016/S2214-109X(20)30285-0. Epub 2020 Jul 2.
6
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27.
7
Co-infections in people with COVID-19: a systematic review and meta-analysis.
J Infect. 2020 Aug;81(2):266-275. doi: 10.1016/j.jinf.2020.05.046. Epub 2020 May 27.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
WINPEPI updated: computer programs for epidemiologists, and their teaching potential.
Epidemiol Perspect Innov. 2011 Feb 2;8(1):1. doi: 10.1186/1742-5573-8-1.
10
Glucocorticoids and invasive fungal infections.
Lancet. 2003 Nov 29;362(9398):1828-38. doi: 10.1016/S0140-6736(03)14904-5.
Zotero 插件